Vyome Holdings Form 4 shows 17,833 merger-related options for director

Rhea-AI Filing Summary

Vyome Holdings, Inc. (HIND) reported a Form 4 insider transaction for a director relating to stock options granted in connection with its merger with Vyome Therapeutics, Inc. The filing shows a stock option (right to buy) covering 17,833 shares of Vyome Holdings common stock at an exercise price of $0.66 per share, granted on 11/13/2025 and expiring on 07/30/2035. These options were issued under the company’s 2025 Equity Incentive Plan following the August 2025 merger in which Raider Lifesciences Inc., a wholly owned subsidiary, merged into Vyome Therapeutics, which now operates as a subsidiary of Vyome Holdings. Of the 17,833 options, 4,458 were fully vested on the grant date, while the remaining 13,375 vest in twelve equal monthly installments beginning on 11/30/2025, subject to continued service. After this transaction, the director beneficially owns 17,833 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tincoff John M. III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,833	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 17,833 shares (Direct)

Footnotes (1)

1. Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tincoff John M. III

(Last) (First) (Middle)

HARVARD SQUARE,

ONE MIFFLIN PLACE, SUITE 400

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vyome Holdings, Inc [ HIND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$0.66	11/13/2025		A(1)		17,833		(2)	07/30/2035	Common Stock	17,833	$0	17,833	D

Explanation of Responses:

1. Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

2. Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ John Tincoff	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Vyome Holdings, Inc. (HIND) report on this Form 4?

The Form 4 reports that a director received a stock option to purchase 17,833 shares of Vyome Holdings common stock at an exercise price of $0.66 per share, granted on 11/13/2025 and held directly.

How do the 17,833 stock options for Vyome Holdings (HIND) vest?

According to the filing, 4,458 options were fully vested on the grant date. The remaining 13,375 options will vest in twelve equal monthly installments starting on 11/30/2025, conditioned on the director’s continued service on each vesting date.

How is the Vyome Holdings (HIND) stock option grant connected to the merger with Vyome Therapeutics?

The filing explains that under the Merger Agreement, each Vyome Therapeutics stock option outstanding before the August 2025 merger was automatically assumed and converted into options to purchase shares of Vyome Holdings common stock, and the reported grant of 17,833 options arises under those merger terms and the 2025 Equity Incentive Plan.

What were the key terms of the merger that led to the Vyome Holdings (HIND) option grant?

The document states that on 08/15/2025, Raider Lifesciences Inc., a wholly owned subsidiary, merged with and into Vyome Therapeutics, Inc., which survived as a subsidiary of Vyome Holdings. After the merger, the issuer was renamed Vyome Holdings, Inc., and Vyome Therapeutics continued under its existing name, with outstanding Vyome Therapeutics options converted into Vyome Holdings options.

When do the reported Vyome Holdings (HIND) stock options expire and how many are owned after the transaction?

The stock option reported on the Form 4 expires on 07/30/2035. Following the reported transaction, the director beneficially owns 17,833 derivative securities (stock options) directly.